253
Participants
Start Date
December 31, 2004
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
eslicarbazepine acetate
oral tablet, 800 mg or 1200 mg once daily
placebo (Part I)
once daily placebo comparator
ESL - Open-label Extension (Part II)
Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
Bial - Portela & Cª, S.A., S. Mamede Do Coronado
Bial - Portela C S.A.
INDUSTRY